Chen Wenwen, Hu Zhigang, Guo Zhigang
Jiangsu Key Laboratory for Molecular and Medical Biotechnology, College of Life Sciences, Nanjing Normal University, 1 Wenyuan Road, Nanjing 210023, China.
Biomedicines. 2023 Nov 27;11(12):3159. doi: 10.3390/biomedicines11123159.
Immunotherapy is a hot area in cancer treatment, and one of the keys to this therapy is the identification of the right tumour-associated or tumour-specific antigen. Cluster of differentiation 24 (CD24) is an emerging tumour-associated antigen that is commonly and highly expressed in various tumours. In addition, CD24 is associated with several cancer-related signalling pathways and closely interacts with other molecules and immune cells to influence tumour progression. Monoclonal antibodies, antibody-drug conjugates (ADCs), chimeric antigen receptor (CAR) T-cell therapy, and CAR-NK cell therapy are currently available for the treatment of CD24. In this review, we summarise the existing therapeutic approaches and possible future directions targeting CD24.
免疫疗法是癌症治疗中的一个热门领域，而这种疗法的关键之一是识别合适的肿瘤相关或肿瘤特异性抗原。分化簇24（CD24）是一种新兴的肿瘤相关抗原，在各种肿瘤中普遍且高表达。此外，CD24与多种癌症相关信号通路有关，并与其他分子和免疫细胞密切相互作用以影响肿瘤进展。目前，单克隆抗体、抗体药物偶联物（ADC）、嵌合抗原受体（CAR）T细胞疗法和CAR-NK细胞疗法可用于治疗CD24。在本综述中，我们总结了针对CD24的现有治疗方法和可能的未来方向。
